These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21557981)

  • 21. Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus.
    Swayne DE; Lee CW; Spackman E
    Avian Pathol; 2006 Apr; 35(2):141-6. PubMed ID: 16595307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the potency, optimal antigen level and lasting immunity of inactivated avian influenza vaccine prepared from H5N1 virus.
    Sasaki T; Isoda N; Soda K; Sakamoto R; Saijo K; Hagiwara J; Kokumai N; Ohgitani T; Imamura T; Sawata A; Lin Z; Sakoda Y; Kida H
    Jpn J Vet Res; 2009 Feb; 56(4):189-98. PubMed ID: 19358446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens.
    Zhang X; Liu M; Liu C; Du J; Shi W; Sun E; Li H; Li J; Zhang Y
    Intervirology; 2011; 54(5):290-9. PubMed ID: 21228535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus.
    Hussein HA; Ahmed BM; Aly SM; El-Deeb AH; El-Sanousi AA; Rohaim MA; Arafa AA; Gadalla MR
    Acta Virol; 2016; 60(3):307-15. PubMed ID: 27640441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine.
    Philippa J; Baas C; Beyer W; Bestebroer T; Fouchier R; Smith D; Schaftenaar W; Osterhaus A
    Vaccine; 2007 May; 25(19):3800-8. PubMed ID: 17403559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoadjuvant effects of hemagglutinating virus of Japan envelope (HVJ-E) on the inactivated H9 subtype avian influenza virus vaccine.
    Zhang Q; Wang Z; Yuan Y; Xue Z; Zhai G; Zuo W; Zhu S; Zhu G; Xu X
    Vet Immunol Immunopathol; 2011 May; 141(1-2):116-23. PubMed ID: 21444118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics.
    Tian G; Zhang S; Li Y; Bu Z; Liu P; Zhou J; Li C; Shi J; Yu K; Chen H
    Virology; 2005 Oct; 341(1):153-62. PubMed ID: 16084554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant fowlpox virus vector-based vaccine completely protects chickens from H5N1 avian influenza virus.
    Qiao C; Jiang Y; Tian G; Wang X; Li C; Xin X; Chen H; Yu K
    Antiviral Res; 2009 Mar; 81(3):234-8. PubMed ID: 19110002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delivery of an inactivated avian influenza virus vaccine adjuvanted with poly(D,L-lactic-co-glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens.
    Singh SM; Alkie TN; Nagy É; Kulkarni RR; Hodgins DC; Sharif S
    Vaccine; 2016 Sep; 34(40):4807-13. PubMed ID: 27543454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An inactivated H5N2 vaccine reduces transmission of highly pathogenic H5N1 avian influenza virus among native chickens.
    Poetri ON; Bouma A; Murtini S; Claassen I; Koch G; Soejoedono RD; Stegeman JA; van Boven M
    Vaccine; 2009 May; 27(21):2864-9. PubMed ID: 19428896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transmission of highly pathogenic avian influenza H5N1 virus in Pekin ducks is significantly reduced by a genetically distant H5N2 vaccine.
    van der Goot JA; van Boven M; Stegeman A; van de Water SG; de Jong MC; Koch G
    Virology; 2008 Dec; 382(1):91-7. PubMed ID: 18848343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains.
    Rauw F; Palya V; Van Borm S; Welby S; Tatar-Kis T; Gardin Y; Dorsey KM; Aly MM; Hassan MK; Soliman MA; Lambrecht B; van den Berg T
    Vaccine; 2011 Mar; 29(14):2590-600. PubMed ID: 21292007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoadjuvant efficacy of CpG plasmids for H9N2 avian influenza inactivated vaccine in chickens with maternal antibodies.
    Pan X; Liu Q; de Jong MCM; Forlenza M; Niu S; Yan D; Teng Q; Li X; Beerens N; Li Z
    Vet Immunol Immunopathol; 2023 May; 259():110590. PubMed ID: 36990004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In ovo vaccination of chicken embryos with experimental Newcastle disease and avian influenza oil-emulsion vaccines.
    Stone H; Mitchell B; Brugh M
    Avian Dis; 1997; 41(4):856-63. PubMed ID: 9454919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccines developed for H5 highly pathogenic avian influenza in China.
    Qiao C; Tian G; Jiang Y; Li Y; Shi J; Yu K; Chen H
    Ann N Y Acad Sci; 2006 Oct; 1081():182-92. PubMed ID: 17135510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pekin and Muscovy ducks respond differently to vaccination with a H5N1 highly pathogenic avian influenza (HPAI) commercial inactivated vaccine.
    Cagle C; To TL; Nguyen T; Wasilenko J; Adams SC; Cardona CJ; Spackman E; Suarez DL; Pantin-Jackwood MJ
    Vaccine; 2011 Sep; 29(38):6549-57. PubMed ID: 21771626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.